{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:39:48Z","timestamp":1790177988406,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.semarthrit.2006.07.003","type":"journal-article","created":{"date-parts":[[2006,9,13]],"date-time":"2006-09-13T07:16:35Z","timestamp":1158131795000},"page":"168-172","source":"Crossref","is-referenced-by-count":41,"title":["Tumor Necrosis Factor-\u03b1 in Inflammatory Myopathies: Pathophysiology and Therapeutic Implications"],"prefix":"10.1016","volume":"36","author":[{"given":"Petros","family":"Efthimiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9388","key":"10.1016\/j.semarthrit.2006.07.003_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semarthrit.2006.07.003_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/jnnp.70.5.569","article-title":"Progress in inflammatory myopathies: good but not good enough","volume":"70","author":"Dalakas","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.semarthrit.2006.07.003_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1034\/j.1600-0404.2002.1o104.x","article-title":"Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers","volume":"105","author":"Schoser","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.semarthrit.2006.07.003_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0889-857X(02)00025-X","article-title":"Possible pathogenic mechanisms in inflammatory myopathies","volume":"28","author":"Lundberg","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.semarthrit.2006.07.003_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-510X(96)00280-8","article-title":"Expression of tumor necrosis factor-alpha in muscles of polymyositis","volume":"146","author":"Tateyama","year":"1997","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.semarthrit.2006.07.003_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0960-8966(98)00126-6","article-title":"Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies","volume":"9","author":"De Bleecker","year":"1999","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.semarthrit.2006.07.003_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00005072-199603000-00009","article-title":"Cytokine expression profile in idiopathic inflammatory myopathies","volume":"55","author":"Tews","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1016\/j.semarthrit.2006.07.003_bib8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2133.2004.06144.x","article-title":"Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis","volume":"151","author":"Caproni","year":"2004","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2006.07.003_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1523-1747.2002.01869.x","article-title":"Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis","volume":"119","author":"Werth","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2006.07.003_bib10","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.1780371206","article-title":"Elevated serum levels of interleukin-1 receptor antagonist in polymyositis\/dermatomyositis","volume":"37","author":"Gabay","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2006.07.003_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s100670070027","article-title":"Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis","volume":"19","author":"Shimizu","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2006.07.003_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-5728(95)00122-0","article-title":"Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls","volume":"63","author":"Lundberg","year":"1995","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2006.07.003_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s004010051165","article-title":"Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis","volume":"99","author":"Kuru","year":"2000","journal-title":"Acta Neuropathol (Berl)"},{"issue":"1","key":"10.1016\/j.semarthrit.2006.07.003_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2990.1998.00092.x","article-title":"Local expression of cytokines in idiopathic inflammatory myopathies","volume":"24","author":"Lepidi","year":"1998","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"9","key":"10.1016\/j.semarthrit.2006.07.003_bib15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/intimm\/12.9.1329","article-title":"Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation","volume":"12","author":"De Rossi","year":"2000","journal-title":"Int Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2006.07.003_bib16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2006.07.003_bib17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2004.032359","article-title":"Contribution of TNF\u03b1 and IL-1\u03b2 to IL-6 production, NF-\u03baB nuclear translocation and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors","volume":"64","author":"Chevrel","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2006.07.003_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11926-003-0053-1","article-title":"Idiopathic inflammatory myopathies: a treatment update","volume":"5","author":"Oddis","year":"2003","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.semarthrit.2006.07.003_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.SMJ.0000153119.37032.8B","article-title":"Role of biological agents in immune-mediated inflammatory diseases","volume":"98","author":"Efthimiou","year":"2005","journal-title":"South Med J"},{"issue":"1","key":"10.1016\/j.semarthrit.2006.07.003_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"issue":"1","key":"10.1016\/j.semarthrit.2006.07.003_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000079547","article-title":"Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up","volume":"52","author":"Hengstman","year":"2004","journal-title":"Eur Neurol"},{"issue":"4","key":"10.1016\/j.semarthrit.2006.07.003_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extended follow-up","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.semarthrit.2006.07.003_bib23","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/rheumatology\/keh268","article-title":"Refractory polymyositis responding to infliximab","volume":"43","author":"Uthman","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.semarthrit.2006.07.003_bib24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/rheumatology\/keh226","article-title":"Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha","volume":"43","author":"Korkmaz","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.semarthrit.2006.07.003_bib25","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/rheumatology\/keh285","article-title":"Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab","volume":"43","author":"Selva-O\u2019Callaghan","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.semarthrit.2006.07.003_bib26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/keh062","article-title":"Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1","volume":"43","author":"Sprott","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl 9","key":"10.1016\/j.semarthrit.2006.07.003_bib27","first-page":"S193","article-title":"Etanercept is effective in the treatment of polymyositis\/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents","volume":"43","author":"Sadeeh","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2006.07.003_bib28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for TNF-inhibitors in the treatment of resistant dermatomyositis and polymyositis","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2006.07.003_bib29","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.07.003_bib30","series-title":"Potentially harmful effects of infliximab treatment in patients with idiopathic inflammatory myopathies","author":"Grundtman","year":"2004"},{"issue":"12","key":"10.1016\/j.semarthrit.2006.07.003_bib31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"issue":"2 suppl 1","key":"10.1016\/j.semarthrit.2006.07.003_bib32","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.semarthrit.2006.07.003_bib33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/rheumatology\/keh700","article-title":"Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab","volume":"44","author":"Marie","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.semarthrit.2006.07.003_bib34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/rheumatology\/41.10.1194","article-title":"Non-Hodgkin\u2019s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab","volume":"41","author":"Roddy","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.semarthrit.2006.07.003_bib35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/rheumatology\/keh539","article-title":"Advanced refractory polymyositis responding to infliximab","volume":"44","author":"Anandacoomarasamy","year":"2005","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017206000977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017206000977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,13]],"date-time":"2019-01-13T03:57:00Z","timestamp":1547351820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017206000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0049017206000977"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2006.07.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}